[Central pathology review. Inclusion criterion for clinical studies of ovarian carcinomas?].

Kommoss, F; Kommoss, S; Schmidt, D; du Bois, A; Pfisterer, J

[Central pathology review. Inclusion criterion for clinical studies of ovarian carcinomas?]. / Histopathologische Zweitbegutachtung. Einschlusskriterium für klinische Studien bei Ovarialkarzinomen?

Kommoss, F; Kommoss, S; Schmidt, D; du Bois, A; Pfisterer, J.

Affiliation

Kommoss F; Institut für Pathologie, Referenzzentrum für Gynäkopathologie, A2/2, 68159 Mannheim. kommoss@gyn-patho.de

Pathologe ; 29 Suppl 2: 157-9, 2008 Nov.

Article in De | MEDLINE | ID: mdl-18726596

Subject(s)

Ovarian Neoplasms/pathology; Referral and Consultation; Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bevacizumab; Carboplatin/administration & dosage; Chemotherapy, Adjuvant; Combined Modality Therapy; Consensus; Diagnostic Errors; Female; Humans; Ovarian Neoplasms/drug therapy; Ovarian Neoplasms/secondary; Ovarian Neoplasms/surgery; Ovariectomy; Ovary/pathology; Paclitaxel/administration & dosage; Precancerous Conditions/pathology; Prospective Studies; Sex Cord-Gonadal Stromal Tumors/pathology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Referral and Consultation Type of study: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Limits: Female / Humans Language: De Journal: Pathologe Year: 2008 Type: Article

Fulltext

XML

PubMed Links

Search on Google